X
Akcea/Ionis’ rare disease drug Waylivra set for EU market after rejection in US
https://pharmaphorum.com/news/akcea-ionis-rare-disease-drug-waylivra-set-for-eu-market-after-rejection-in-us/
Ionis
Alnylam’s Onpattro is first ever FDA-approved RNAi drug
Onpattro will cost $450,000 a year
Ionis hit by safety concerns, rivals Alnylam benefit
Biotech insists drug for rare inherited disorder is still approvable.
Biogen courts controversy with $750k-a-year rare disease drug
Biogen’s SMA treatment approved – but price is $125,000 per dose
Biogen to file spinal muscular atrophy drug
Phase 3 success triggers $75m payment to Ionis.